

**Efficacy of the combination of venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia**

---

*Ibrahim Aldoss,<sup>1</sup> Dongyun Yang,<sup>2</sup> Ahmed Aribi,<sup>1</sup> Haris Ali,<sup>1</sup> Karamjeet Sandhu,<sup>1</sup> Monzr M. Al Malki,<sup>1</sup> Matthew Mei,<sup>1</sup> Amandeep Salhotra,<sup>1</sup> Samer Khaled,<sup>1</sup> Ryotaro Nakamura,<sup>1</sup> David Snyder,<sup>1</sup> Margaret O'Donnell,<sup>1</sup> Anthony S. Stein,<sup>1</sup> Stephen J. Forman,<sup>1</sup> Guido Marcucci<sup>1</sup> and Vinod Pullarkat<sup>1</sup>*

*<sup>1</sup>Department of Hematology and Hematopoietic Cell Transplantation, Gehr Family Center for Leukemia Research and <sup>2</sup>Department of Information Sciences, Division of Biostatistics, City of Hope, Duarte, CA, USA*

*Correspondence: [vpullarkat@coh.org](mailto:vpullarkat@coh.org)  
doi:10.3324/haematol.2018.188094*

	AGE	DISEASE	PRIOR ALLO HCT	PRIOR HMA	BEST RESPONSE	CYTOGENETICS	MUTATION PROFILE
AML01	78	De novo	YES	NO	CR	46,XY,del(17)(q23)	PHF6
AML02	76	de novo	NO	YES	CR	46,XY	CEBPA, ZRSR2, TET2
AML03	76	de novo	NO	YES	CR	48,XY,+19,+21	RUNX1, SETBP1, SRSF2
AML04	62	de novo	YES	YES	CR	46,XX,del(7)(q22q36)	DNMT31, IDH1
AML05	60	de novo	YES	NO	CR	46,XY,t(2;12)(p13;p13)	BCOR, DNMT3A, IDH2, STAG2
AML06	63	de novo	NO	NO	CRi	47,XX,+i(13)(q10)	DNMT3A, EZH2, FLT3-TKD
AML07	69	de novo	NO	NO	CRi	46,XX	DNMT3A, SRSF2, TET2, TP53, RUNX1
AML08	66	Therapy-related	NO	NO	CRi	46,XY,del(5)(q13q33),del(7)(p11p13),add(8)(q24),del(12)(p11),del(12)(p11),del(16)(q12q24)	TET2, TP53
AML09	43	De novo	YES	YES	CR	46,XX	NEGATIVE
AML10	62	De novo	NO	NO	MFLS	43,XX,add(1)(p22),der(2)t(2;17)(q33;q21),der(5)t(1;5)(p32;q15),der(6)t(2;6)(q33;p23),der(15;20)t(15;20)(p11;q13)ins(20;21)(q13;q22)dup(21)(q22q21),-17,-21	BCOR, TP53
AML11	19	De novo	NO	YES	CR	46,XX,t(6;9)(p22;q34)	DEK-NUP214, IDH2, PTPN11
AML12	54	Secondary	YES	YES	MFLS	47,XX,t(3;7)(q21;q31),del(17)(p11),+21	CSF3R
AML13	63	Therapy-related	NO	NO	Refractory	46,XX,t(4;17)(q21;p13),t(9;11)(p22;q23)	GATA2, FLT3-ITD
AML14	58	de novo	YES	YES	Refractory	46,XY,i(17)(q10)	CEBPA, CSF3R and GATA2 by NGS
AML15	53	de novo	YES	YES	Refractory	46,XX,del(11)(q23q25)	FLT3-ITD
AML16	58	de novo	YES	NO	Refractory	46,XY	DNMT3A, FLT3-ITD, NPM1
AML17	55	Therapy-related	NO	NO	Refractory (PR)	45,xx,-7	PTPN11, KRAS
AML18	19	De novo	NO	NO	Refractory	46,XY,t(11;17)(q23;q21) with MLL translocation	KMT2A-MLLT6, U2AF1